Can Take­da ac­tu­al­ly close its $65B deal to buy Shire? Maybe, but an­a­lysts aren't sure they should

Take­da has upped its of­fer to buy Shire $SH­PG for a mix of stock and cash worth close to $65 bil­lion, which is good enough for the Lex­ing­ton, MA-based biotech to ex­tend the dead­line on their talks to May 8 af­ter de­ter­min­ing they were close to fi­nal­iz­ing a pact.

Late Tues­day Shire re­port­ed that Take­da had upped its bid to £27.26 in new Take­da shares and £21.75 in cash, com­ing to £49 a share. That rings up at 0.839 new Take­da shares and $30.33 for each Shire share — or close to $65 bil­lion, with Take­da tack­ing about $2.5 bil­lion on its pre­vi­ous of­fer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.